Analisis Drug Related Problems pada Pasien Kanker Padat Stadium Lanjut yang Menjalani Terapi Paliatif di Rumah Sakit Kanker Dharmais

EMA NILLAFITA PUTRI KUSUMA* -  , Indonesia

DOI : 10.33371/ijoc.v9i2.376

ABSTRACTThe goal of palliative care is to increase the quality of life and to reduce the symptomp, but it often increases the complexity of patients therapy. The aim of this study is to evaluate prevalance, the risk factor, and the profile of Drug Related Problems (DRPs) from the palliative therapy patient who suffer from solid cancer at Dharmais Hospital National Cancer Center. This is a cross sectional study and the data was taken from the patients medical records starting from March to June 2011. The patient characteristics who followed this study were 33 patients women (68.8%), and the frequent cases of solid cancer was breast cancer, i.e about 15 patients (31.3%). Most of the patients (64.6%) were in palliative care. Adverse reactions occurred in 70.1% patienst and 66.2% patients got potential adverse reaction. Only 5.7% drug-drug interactions were detected with moderate significance. About 15.0% drug interactions caused by the use of morphine, and amitriptyline at the same time. The risk of incident adverse reactions were influenced by age, sex,history of curative chemotherapy regimen, comorbidities, and the number of drug use. The increasing risk of drug interaction incident was the influenced by the number of drugs using ( > 5 drugs) and if the patient had a comorbidities. Most of patients in the palliative care would get the DRP but drug interactions did not always occur.ABSTRAKTerapi paliatif bertujuan meningkatkan kualitas hidup dan mengurangi gejala, namun akan menambah kompleksitas terapi. Penelitian ini bertujuan mengevaluasi prevalensi, faktor risiko, dan profil kejadian Drug Related Problems (DRPs) terapi paliatif pasien kanker padat stadium lanjut. Penelitian ini adalah penelitian potong lintang. Dan data diambil dari rekam medis pasien bulan Maret Juni 2011. Karakteristik pasien, 33 orang (68,8%) perempuan, dan kasus kanker padat terbesar adalah kanker payudara sebanyak 15 orang (33,3%). Sebagian besar pasien kanker padat stadium lanjut (64,6%) hanya menjalani satu kali terapi paliatif. Reaksi obat yang tidak diinginkan (ROTD) termanifestasi dialami 70,1% subyek uji dan 66,2% uji berpotensi mengalami ROTD. Interaksi obat dengan signifikansi moderate ditemui pada 5,7% terapi pasien. Sebesar 15,0% interaksi tersebut akibat penggunaan morfin dan amitriptilin bersama. Risiko ROTD meningkat karena usia, jenis kelamin, riwayat pemberian regimen kemoterapi kuratif, penyakit penyerta, dan jumlah obat yang digunakan. Peningkatan risiko kejadian interaksi obat dipengaruhi oleh penggunaan > 5 jenis obat dan adanya penyakit penyerta. Pasien kanker padat stadium lanjut yang menjalani terapi paliatif pada umumnya mengalami ROTD, namun jarang ditemukan interaksi obat.
Keywords
Adverse drug reaction; drug interaction; drug related problems (DRPs); palliative care of solid tumor
  1. Bidang Rekam Medis RSK Dharmais : 10 Besar Kanker Kasus
  2. Baru Tahun 2009 dan 2010 Rumah Sakit Kanker Dharmais.
  3. Jakarta: RS Kanker Dharmais; 2010.
  4. Anonim. Merawat Hingga Akhir Hayat: Perawatan Paliatif
  5. Pada Penderita Kanker. Dokter Kita 1 Januari 2011; hal 23-25
  6. kolom 1-2.
  7. Koh Y, Kutty FB, Li SC. Drug-Related Problems In Hospitalized
  8. Patients On Polypharmacy: The Influence of Age And Gender,
  9. J Therapeutics and Clinical Risk Management. 2005:1(1):39-
  10. Koh NY, Koo WH. Polypharmacy in Palliative Care : Can it
  11. be Reduced?. Singapore Med J. 2002:43(6):279-83.
  12. Lau PM, Stewart K, Dooley M. The Ten Most Common Adverse
  13. Drug Reaction (ADR) in oncology patients: do they matter
  14. to you? Support Care Cancer. 2004; 12: 626-33.
  15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
  16. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
  17. Anonim. Fact Sheet: Metastatic Cancer. America : National
  18. Cancer Institute, National Institutes of Health USA; 2013.
  19. Weigelt B, Peterse JL, Vant Veer LJ. Breast cancer metastasis:
  20. markers and models. Nature Review Cancer J. 2005 Aug;
  21. (8):591-602.
  22. Anonim. Advance Cancer [serial online] 2012. Didapat dari
  23. http://www.cancer.org/treatment/understandingyourdiagnosis/
  24. advancedcancer/advanced-cancer-detailed-guide-toc.
  25. Naranjo CA, Busto U, Sellers EM, et al. A method for
  26. estimating the probability of adverse drug reactions. Clinical
  27. Pharmacology and Therapeutics. 1981;30(2):239-245.
  28. Lee A. Adverse Drug Reaction. 2nd ed. Great Britian:
  29. Pharmaceutical Press; 2006.
  30. Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer-Ruskamp
  31. FM. Adverse drug reaction and polypharmacy in eldery in
  32. general practice. Eur J Clin Pharmacol. 1999 Sep;55(7):533-
  33. Maggiore RJ, Gross CP, Huria A. Polypharmacy in older adults
  34. with cancer. Oncologist. 2010;15(5):507-22.
  35. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA,
  36. Krzyzanowska MK. Potential Drug Interaction and Duplicate
  37. Prescription Among Cancer Patients. J Natl Cancer Inst.
  38. ;99(8):592-600.
  39. World Health Organization. Cancer Control, Knowledge into
  40. Action. WHO Giude for Effective Programmes : Palliative
  41. Care. Geneva : World Health Organization; 2007.
  42. Departemen Kesehatan Republik Indonesia. Keputusan Menteri
  43. Kesehatan Republik Indonesia Nomor : 812/Menkes/SK/
  44. VII/2007 Tentang Kebijakan Perawatan Paliatif. Departemen
  45. Kesehatan Republik Indonesia 2007.
  46. Anonim, Drug Interaction Checker [serial online]. Didapat
  47. dari URL:httpwww.mims.com.
  48. Fradgley, S. Interaksi obat. Dalam : Aslam M, Tan CK, Prayitno
  49. A, penyunting. Farmasi Klinis (Clinical Pharmacy) Menuju
  50. Pengobatan Rasional dan Penghargaan Pilihan Pasien. Jakarta:
  51. PT. Elex Media Komputindo Kelompok Gramedia. 2003.
  52. 134p.
  53. World Health Organization. Cancer. Geneva : World Health
  54. Organization; 2007.

Full Text:
Article Info
Submitted: 2015-09-23
Published: 2015-07-01
Section: Research Articles
Article Statistics: 458 392